How should a transplant recipient who is EBV‑seropositive be managed and monitored for post‑transplant lymphoproliferative disorder?

Management of EBV-Seropositive Transplant Recipients

EBV-seropositive transplant recipients require prospective EBV DNA monitoring only if they have high-risk features, with weekly quantitative PCR testing starting by 4 weeks post-transplant and continuing for at least 4 months, followed by preemptive rituximab therapy if significant DNAemia develops. 1

Risk Stratification in EBV-Seropositive Recipients

While EBV-seropositive recipients have substantially lower PTLD risk compared to seronegative recipients (particularly D+/R- pairs), they are not risk-free. The key distinction is identifying which seropositive recipients warrant intensive monitoring:

High-Risk EBV-Seropositive Recipients Requiring Monitoring:

• T-cell depleted transplants
• HLA-mismatched or haploidentical transplants
• Recipients of cord blood transplants
• Those receiving ATG or alemtuzumab conditioning
• Patients with severe acute or chronic GvHD requiring intensive immunosuppression
• Recipients of second transplants
• Post-splenectomy patients 1

Low-Risk EBV-Seropositive Recipients (No Routine Monitoring):

• HLA-identical family transplant recipients without T-cell depletion and without GvHD 1

Important caveat: Recent data from lung transplantation suggests EBV surveillance in seropositive adult recipients has limited utility, with low positive predictive values (14.7% for moderate DNAemia, 33.3% for high-grade DNAemia) 2. However, this conflicts with established guidelines for high-risk hematopoietic stem cell transplant recipients where monitoring remains standard.

Monitoring Protocol for High-Risk Seropositive Recipients

Specimen and Frequency:

• Specimen: Whole blood, plasma, or serum are all acceptable 1
• Start: No later than 4 weeks post-transplant (earlier if multiple risk factors present) 1
• Frequency: Weekly testing in high-risk PCR-negative patients; more frequent if rising DNAemia 1
• Duration: Minimum 4 months post-transplant 1
• Extended monitoring: Continue beyond 4 months if poor T-cell reconstitution, ongoing severe GvHD treatment, or early EBV reactivation occurred 1

No Specific Threshold Exists:

The guidelines explicitly state no universal EBV DNA threshold can be recommended for preemptive intervention 1. Centers use varying thresholds (1,000-40,000 copies/mL depending on specimen type), and the rate of increase is clinically significant 1. Local experience should guide center-specific cutoffs.

Preemptive Therapy for Significant DNAemia

When significant EBV DNAemia develops without clinical symptoms:

1. Rituximab 375 mg/m² weekly (1-4 doses) until DNAemia negativity 1
2. Reduce immunosuppression whenever possible (except in uncontrolled severe acute/chronic GvHD) 1
3. Consider EBV-specific CTLs if available 1
4. Do NOT use antiviral drugs (acyclovir, ganciclovir, foscarnet, cidofovir) - they are ineffective against latent EBV 1

Response monitoring: Expect ≥1 log₁₀ decrease in EBV DNA within the first week of rituximab therapy 1

Treatment of Established PTLD

If PTLD develops (proven by biopsy with EBER in situ hybridization):

First-Line:

• Rituximab 375 mg/m² weekly (up to 4 doses) 1
• Combined with immunosuppression reduction 1
• Rituximab achieves positive outcomes in ~70% of patients 1

Second-Line (if rituximab fails):

• EBV-specific CTLs or donor lymphocyte infusion 1
• Chemotherapy ± rituximab 1

CNS PTLD:

• Rituximab ± chemotherapy (high-dose methotrexate/cytarabine) 1
• Consider intrathecal rituximab, EBV-CTLs, or radiotherapy 1

Critical Pitfalls to Avoid

1. Do not use antiviral prophylaxis or treatment - no efficacy against latent EBV 1
2. Do not use interferon or IVIG for prophylaxis or treatment 1
3. Avoid excessive rituximab doses - additional doses beyond 4 may downregulate CD20 expression and decrease efficacy 1
4. Monitor for rituximab complications - hypogammaglobulinemia, cytopenias, and bacterial infections 1
5. Do not rely solely on immunosuppression reduction post-HSCT - rarely successful alone and may precipitate GvHD/rejection 1

Donor Selection Considerations

For EBV-seropositive recipients, an EBV-seropositive donor may be beneficial due to presence of EBV-positive CTLs in the graft 1, though this is a weak recommendation (CIII evidence level).